These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2936800)

  • 1. Differentiation of Mycobacterium chelonei from M. fortuitum by ciprofloxacin susceptibility.
    Collins CH; Yates MD; Uttley AH
    J Hyg (Lond); 1985 Dec; 95(3):619-21. PubMed ID: 2936800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to cefmetazole.
    Casal MJ; Rodriguez FC; Benavente MC
    Antimicrob Agents Chemother; 1985 Feb; 27(2):282-3. PubMed ID: 3857020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro susceptibility of mycobacteria to ciprofloxacin.
    Collins CH; Uttley AH
    J Antimicrob Chemother; 1985 Nov; 16(5):575-80. PubMed ID: 2934361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ability of ciprofloxacin but not pipemidic acid to differentiate all three biovariants of Mycobacterium fortuitum from Mycobacterium chelonae.
    Steele LC; Wallace RJ
    J Clin Microbiol; 1987 Feb; 25(2):456-7. PubMed ID: 3818939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare.
    Fenlon CH; Cynamon MH
    Antimicrob Agents Chemother; 1986 Mar; 29(3):386-8. PubMed ID: 2940969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Ro 23-6240 on sensitive and resistant intracellular mycobacteria.
    Easmon C; Verity L
    Eur J Clin Microbiol; 1987 Apr; 6(2):165-6. PubMed ID: 3109896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.
    Swenson JM; Wallace RJ; Silcox VA; Thornsberry C
    Antimicrob Agents Chemother; 1985 Dec; 28(6):807-11. PubMed ID: 4083863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of ciprofloxacin against clinical isolates of mycobacteria resistant to antimycobacterial drugs.
    Marinis E; Legakis NJ
    J Antimicrob Chemother; 1985 Oct; 16(4):527-30. PubMed ID: 2933382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of Mycobacterium gordonae from Mycobacterium scrofulaceum and Mycobacterium szulgai by susceptibility to enoxacin (antimycobacterial activity of enoxacin).
    Tsukamura M
    Microbiol Immunol; 1986; 30(9):931-3. PubMed ID: 3467156
    [No Abstract]   [Full Text] [Related]  

  • 10. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei.
    Wallace RJ; Jones DB; Wiss K
    Rev Infect Dis; 1981; 3(5):898-904. PubMed ID: 7339821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
    Davies S; Sparham PD; Spencer RC
    J Antimicrob Chemother; 1987 May; 19(5):605-9. PubMed ID: 3112094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simple, new test for rapid differentiation of the Mycobacterium fortuitum complex.
    Casal MJ; Rodriguez FC
    J Clin Microbiol; 1981 May; 13(5):989-990. PubMed ID: 7240405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Evidence is based on plasmid analysis, mutational frequencies, and aminoglycoside-modifying enzyme assays.
    Wallace RJ; Hull SI; Bobey DG; Price KE; Swenson JM; Steele LC; Christensen L
    Am Rev Respir Dis; 1985 Aug; 132(2):409-16. PubMed ID: 4026065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.
    Gay JD; DeYoung DR; Roberts GD
    Antimicrob Agents Chemother; 1984 Jul; 26(1):94-6. PubMed ID: 6236748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility of mycobacterium fortuitum and mycobacterium chelonei to cefoxitin.
    Casal M; Rodríguez F
    Tubercle; 1982 Jun; 63(2):125-7. PubMed ID: 7179478
    [No Abstract]   [Full Text] [Related]  

  • 16. Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents.
    Wallace RJ; Dalovisio JR; Pankey GA
    Antimicrob Agents Chemother; 1979 Nov; 16(5):611-4. PubMed ID: 526002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of some quinoline derivatives against Mycobacterium fortuitum.
    Valero-Guillén PL; Martín-Luengo F; Quintanilla I
    J Antimicrob Chemother; 1985 Feb; 15(2):254-5. PubMed ID: 3980314
    [No Abstract]   [Full Text] [Related]  

  • 18. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
    Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
    Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic resistance in
    Jayasingam SD; Zin T; Ngeow YF
    Int J Mycobacteriol; 2017; 6(4):387-390. PubMed ID: 29171453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium fortuitum and Mycobacterium chelonei to augmentin.
    Casal M; Rodriguez F; Benavente M; Luna M
    Eur J Clin Microbiol; 1986 Aug; 5(4):453-4. PubMed ID: 3093225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.